{"gene":"OPRK1","run_date":"2026-04-29T11:37:57","timeline":{"discoveries":[{"year":2008,"finding":"An insertion/deletion variant located ~1986 bp upstream of the OPRK1 translation start site functions as a regulatory element; the longer allele (with the indel) reduced OPRK1 transcriptional activity by approximately half in transient transfection promoter assays, establishing this as a functional regulatory variation affecting KOR expression levels.","method":"Transient transfection promoter assay (luciferase reporter), PCR genotyping, family-based association analysis","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro promoter/reporter assay demonstrating functional consequence of the variant on transcription","pmids":["18319328"],"is_preprint":false},{"year":2015,"finding":"OPRK1 promoter hypermethylation reduces OPRK1 gene expression; luciferase reporter assay demonstrated that a CpG-containing fragment of the OPRK1 promoter significantly increased reporter gene expression (~2.25-fold), indicating that methylation of this region suppresses KOR expression.","method":"Bisulphite pyrosequencing for methylation quantification; luciferase reporter gene assay","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 1 reporter assay but single lab, single paper with moderate methods","pmids":["26300544"],"is_preprint":false},{"year":2011,"finding":"KOR (encoded by OPRK1) is phosphorylated at Ser369 in its C-terminal tail by G protein receptor kinase (GRK) upon agonist activation, initiating the β-arrestin-dependent desensitization cascade; phospho-selective antibodies against this site were developed and validated to track KOR activation in vivo following stress or behavioral stimuli.","method":"Phospho-selective antibody development and immunohistochemical validation; behavioral and pharmacological manipulation in rodents","journal":"Methods in molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 — phospho-specific antibody validated against defined site, single lab","pmids":["21370032"],"is_preprint":false},{"year":2021,"finding":"Agonist-promoted phosphorylation of mouse KOR at four C-terminal residues (mutated to Ala in K4A mice) plays sex-dependent roles in tolerance and conditioned place aversion (CPA): male K4A mice showed attenuated tolerance to anti-scratch effects and retained CPA to U50,488H, while female K4A mice showed no CPA, revealing that KOR phosphorylation mediates behavioral endpoints in a sex-specific manner without affecting acute anti-pruritic or hypo-locomotor effects.","method":"Knockin mouse (K4A mutant), autoradiography ([3H]U69,593 binding), behavioral assays (scratch, locomotion, conditioned place aversion, tolerance), in vivo pharmacology","journal":"Neuropharmacology","confidence":"High","confidence_rationale":"Tier 1-2 — in vivo genetic mutagenesis of phosphorylation sites with multiple defined behavioral readouts, validated receptor expression","pmids":["34736959"],"is_preprint":false},{"year":2022,"finding":"Peripheral conditional knockout of adenylyl cyclase 3 (AC3) in DRGs eliminated the analgesic effect of a KOR agonist and blocked KOR-mediated inhibition of voltage-gated potassium (Kv) channels, demonstrating that AC3 is required for KOR/Gαi-o signaling and possibly via direct KOR-AC3 protein interaction in peripheral sensory neurons.","method":"Conditional KO (AC3 CKO in L3/L4 DRGs), Kv channel current recordings, cAMP measurements, behavioral nociception assays, Western blot, pharmacological rescue","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 1-2 — genetic KO with electrophysiology, biochemistry, and behavioral validation across multiple orthogonal approaches","pmids":["34914639"],"is_preprint":false},{"year":2012,"finding":"KOR expressed on murine macrophage J774 cells is functionally active: ligation with Dynorphin-A(1-17) (but not truncated Dynorphin-A(2-17) which lacks KOR binding) triggers ERK1/2 phosphorylation, and IFN-γ upregulates KOR expression at both transcriptional and protein levels.","method":"FACS, immunocytochemistry, Western blot (ERK1/2 phosphorylation), RT-PCR, IFN-γ stimulation","journal":"Journal of neuroimmunology","confidence":"Medium","confidence_rationale":"Tier 2 — functional signaling assay with appropriate negative control (Dynorphin-A(2-17)), single lab","pmids":["22424981"],"is_preprint":false},{"year":2015,"finding":"KOR-Cre knockin mice, in which Cre replaces the initial OPRK1 coding sequence, revealed that KOR is expressed in cerebral cortex, nucleus accumbens, striatum, as well as non-neuronal tissues including epithelium, heart, lung, liver, and retinal bipolar/amacrine cells, with recombination detectable by embryonic day 14.5.","method":"Knockin mouse (Cre recombinase replacing Oprk1 coding sequence), reporter recombination assay, immunohistochemistry, live imaging","journal":"Genesis","confidence":"Medium","confidence_rationale":"Tier 2 — direct genetic reporter of endogenous Oprk1 expression, cell-type localization validated in vivo","pmids":["26575788"],"is_preprint":false},{"year":2015,"finding":"Dynorphin peptides promiscuously stimulate G protein signaling (measured by [35S]GTPγS binding) at multiple receptors in striatal membranes and are not selective for KOR; by contrast, the small-molecule agonist U69,593 is highly selective for KOR in this endogenous system. norBNI and 5'GNTI maintain full potency and efficacy against dynorphin-stimulated signaling even in KOR knockout striatum, demonstrating their non-selectivity for KOR in this context.","method":"[35S]GTPγS binding assay in striatal membrane preparations from WT, KOR-KO, and MOR-KO mice; pharmacological characterization of agonists and antagonists","journal":"Neuropharmacology","confidence":"High","confidence_rationale":"Tier 1-2 — rigorous in vitro assay in endogenous tissue using multiple genetic controls (KO mice), replicated across ligand classes","pmids":["26160155"],"is_preprint":false},{"year":2020,"finding":"VTA KOR activation mediates aversion-induced reductions in striatal dopamine required for learned avoidance: intra-VTA KOR blockade attenuated real-time aversion-induced dopamine decreases and prevented avoidance behavior; intra-nucleus accumbens D2 receptor agonism (mimicking reduced dopamine tone) also prevented avoidance, placing VTA KOR upstream of dopamine-dependent striatal aversion circuitry.","method":"Site-specific pharmacology (intra-VTA norBNI), real-time dopamine voltammetry, intra-NAc D2 agonism, behavioral avoidance assay in rats","journal":"Neuropharmacology","confidence":"High","confidence_rationale":"Tier 2 — genetic/pharmacological epistasis with real-time neurochemical readout and behavioral endpoint, mechanistic pathway defined","pmids":["32057802"],"is_preprint":false},{"year":2022,"finding":"The KOR structure in complex with the antagonist JDTic (crystal structure solved in 2012) and a more recent active-state KOR structure together reveal atomic details of the ligand binding pocket, subtype selectivity determinants, and receptor activation mechanisms including distinct contacts for agonists versus antagonists.","method":"X-ray crystallography (inactive state with JDTic); structural determination of active state KOR","journal":"Handbook of experimental pharmacology","confidence":"High","confidence_rationale":"Tier 1 — crystallographic structures of both inactive and active receptor states with functional pharmacological validation","pmids":["33945028"],"is_preprint":false},{"year":2023,"finding":"Activation of KOR by famotidine (identified via structure-based virtual screening) promotes oligodendrocyte precursor cell (OPC) maturation and CNS remyelination through the KOR/STAT3 signaling pathway, as demonstrated in vitro and in vivo demyelinating disease models.","method":"Structure-based virtual screening, in vitro OPC differentiation assays, in vivo remyelination model, Western blot (STAT3 pathway), pharmacological validation","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2 — complementary in vitro and in vivo models with pathway identification (KOR/STAT3), single lab","pmids":["38692525"],"is_preprint":false},{"year":2022,"finding":"Overexpression of Oprk1 in VTA dopaminergic neurons (using TH::Cre rats with conditional inducible Cre-Lox system) recapitulated phenotypes of alcohol dependence, including escalated alcohol self-administration and depressive-like behavior, demonstrating that KOR signaling specifically within VTA DA neurons is sufficient to drive maladaptive behavioral regulation associated with alcohol dependence.","method":"Conditional Oprk1 overexpression (Cre-Lox in TH::Cre rats), operant alcohol self-administration, affective behavior assays, RT-PCR and functional KOR assays in VTA","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — cell-type-specific gain-of-function with defined behavioral phenotype, single lab","pmids":["36764577"],"is_preprint":false},{"year":2022,"finding":"Activation of KOR inhibits estrogen receptor (ER)-positive breast cancer cell proliferation and promotes apoptosis; gene ontology and PPI network analysis followed by XBP1 silencing experiments identified KOR-ER-XBP1 as the downstream signaling pathway mediating the anti-tumor effects of KOR agonists in MCF-7 and T47D cells.","method":"Cell viability and apoptosis assays in ER+ breast cancer cell lines, siRNA knockdown of XBP1, GO/KEGG pathway analysis, PPI network analysis","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2 — functional loss-of-function (XBP1 KD) confirms pathway placement, in vitro only, single lab","pmids":["37708692"],"is_preprint":false},{"year":2016,"finding":"KOR knockout (KOR-KO) mice showed significantly increased mechanical allodynia after intra-articular MIA injection compared to WT mice, and demonstrated increased microglial activation in the lumbar spinal cord, alterations in CRF in the amygdala and hippocampus, and down-regulation of histone 3 acetylation in the amygdala, establishing the dynorphin/KOR system's role in modulating nociceptive, emotional, and cognitive dimensions of joint pain.","method":"KOR-KO and PDYN-KO mice, MIA joint pain model, behavioral tests (elevated plus maze, object recognition, anhedonia), immunohistochemistry, Western blot","journal":"Neuropharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with multiple behavioral and molecular phenotype readouts, single lab","pmids":["27567942"],"is_preprint":false},{"year":1999,"finding":"Antisense oligodeoxynucleotide mapping of the three exons of KOR-1 revealed that analgesia produced by dynorphin B and alpha-neoendorphin differs mechanistically from U50,488H analgesia: probes targeting all three exons blocked U50,488H analgesia, while dynorphin B and alpha-neoendorphin showed distinct antisense probe selectivity profiles, indicating they act via different receptor mechanisms (kappa1b site) despite sharing sensitivity to norBNI.","method":"Antisense oligodeoxynucleotide exon mapping in vivo (mouse analgesia), kappa1-selective antagonist (norBNI) challenge","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 — systematic antisense mapping across all three exons with multiple ligands, single lab","pmids":["10224306"],"is_preprint":false},{"year":2023,"finding":"miR-144-3p directly suppresses Oprk1/KOR expression: luciferase assay confirmed that miR-144-3p exerts an inhibitory effect on Oprk1 expression in PC12 cells; nicotine dependence and withdrawal decreased miR-144-3p and increased Oprk1/KOR in prefrontal cortex, nucleus accumbens, and hippocampus.","method":"miRNA sequencing, qRT-PCR, Western blot, luciferase reporter assay for miR-144-3p/Oprk1 interaction","journal":"Nicotine & tobacco research","confidence":"Medium","confidence_rationale":"Tier 1 — luciferase assay validates miR-144-3p targeting of Oprk1 3'UTR, single lab","pmids":["37455648"],"is_preprint":false},{"year":2023,"finding":"Activation of KOR in the insular cortex blocked pain-related aversive memory behaviors, and subsequent experiments showed that activation of GABAergic neurons in the insular cortex reversed the effect of KOR activation, placing KOR upstream of GABAergic neuron activity in this circuit; electroacupuncture-mediated block of pain aversive memory was reversed by either GABAergic neuron activation or KOR inhibition in the insular cortex.","method":"Chemogenetics (DREADD), pharmacology (KOR agonist/antagonist injection into insular cortex), behavioral assays (carrageenan pain-aversive memory model) in mice","journal":"Cerebral cortex","confidence":"Medium","confidence_rationale":"Tier 2 — chemogenetic and pharmacological epistasis with defined circuit position, single lab","pmids":["37679857"],"is_preprint":false},{"year":2022,"finding":"Difelikefalin (peripherally restricted KOR agonist) produces diuresis predominantly through central KOR pathways: ICV norBNI (central KOR blockade) markedly attenuated difelikefalin-induced urine output, while peripheral norBNI prevented all responses; electrolyte reabsorption effects were mediated through peripheral KOR pathways, demonstrating distinct central vs. peripheral KOR pathway functions for diuresis and electrolyte handling.","method":"ICV vs. IV norBNI pretreatment in conscious catheterized rats, urine output and electrolyte measurements, cardiovascular monitoring","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological dissection of central vs. peripheral KOR pathways with functional readouts, single lab","pmids":["36202183"],"is_preprint":false},{"year":2006,"finding":"KOR immunoreactivity was found predominantly in OFF (86%) and NEUTRAL (80%) cells but rarely in ON (13%) cells in the rostral ventromedial medulla (RVM); most KOR-immunoreactive cells (16 of 17) also contained GAD67, identifying KOR-expressing neurons in the RVM as predominantly GABAergic, consistent with KOR agonists directly inhibiting off and neutral cell activity.","method":"Extracellular recording of RVM neurons in vivo, juxtacellular biotinamide labeling, immunofluorescence for KOR and GAD67","journal":"Journal of neurophysiology","confidence":"Medium","confidence_rationale":"Tier 2 — direct co-localization of functional cell-type classification with KOR and GAD67 immunoreactivity, single lab","pmids":["17005613"],"is_preprint":false},{"year":2022,"finding":"Dynorphin/KOR system inhibits neuronal autophagy by activating the mTOR signaling pathway: overexpression of prodynorphin in epileptic rats activated mTOR, inhibited autophagy markers (LC3, GFP-LC3 puncta), and reduced neuronal apoptosis; rapamycin (mTOR inhibitor) reversed the dynorphin/KOR-mediated anti-autophagy and anti-apoptotic effects in Mg2+-free-induced seizure-like neurons.","method":"Prodynorphin overexpression in vivo (pilocarpine epilepsy model), Mg2+-free in vitro seizure model, Western blot (mTOR pathway), TUNEL/flow cytometry apoptosis, GFP-LC3 autophagy assay, pharmacological rescue with rapamycin","journal":"Cell biology international","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro and in vivo models with pharmacological epistasis (rapamycin rescue), single lab","pmids":["35989483"],"is_preprint":false},{"year":2025,"finding":"Triazole 187, a G protein signaling-biased KOR agonist, suppresses itch without sedation (no reduction in spontaneous locomotion) and produces anxiolytic-like behaviors, demonstrating that G protein-biased KOR agonism can dissociate antipruritic effects from sedation; it also produces markedly less diuresis (30% of U50,488H at 188-fold the antipruritic potency dose) compared to unbiased KOR agonists.","method":"In vitro G protein/β-arrestin signaling assays, behavioral pharmacology (locomotion, itch, anxiety, diuresis) in mice","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 1-2 — biased signaling characterization with multiple behavioral endpoint dissociation, preprint, single lab","pmids":["40027836"],"is_preprint":true}],"current_model":"OPRK1 encodes the kappa opioid receptor (KOR), a GPCR that, upon activation by dynorphin or exogenous agonists, couples to Gαi/o to inhibit cAMP (requiring peripheral AC3 for full signaling), activates ERK1/2 and p38 MAPK, and undergoes GRK-mediated phosphorylation at Ser369 in its C-terminal tail initiating β-arrestin-dependent desensitization; KOR activation in the mesolimbic dopamine system (particularly VTA) suppresses dopamine release to mediate aversive learning and modulate reward, while its expression is regulated epigenetically by promoter methylation and by miR-144-3p, and a functional insertion/deletion in the promoter region reduces transcription by ~50%, contributing to individual differences in addiction vulnerability."},"narrative":{"teleology":[{"year":1999,"claim":"Antisense exon mapping revealed that endogenous dynorphin peptides and synthetic KOR agonists engage distinct receptor mechanisms despite shared antagonist sensitivity, establishing that OPRK1 gene products can mediate pharmacologically distinguishable kappa opioid activities.","evidence":"Antisense oligodeoxynucleotide targeting of KOR-1 exons in mouse analgesia models with multiple ligands","pmids":["10224306"],"confidence":"Medium","gaps":["Molecular identity of the kappa1b site was not resolved","No receptor mutagenesis or binding data to confirm distinct receptor configurations"]},{"year":2006,"claim":"Identification of KOR expression predominantly on GABAergic OFF and NEUTRAL cells in the rostral ventromedial medulla established a circuit-level mechanism for KOR modulation of descending pain control.","evidence":"Juxtacellular labeling with immunofluorescence for KOR and GAD67 in functionally classified RVM neurons in vivo","pmids":["17005613"],"confidence":"Medium","gaps":["Functional consequence of KOR activation on these specific cell types was not directly tested electrophysiologically","Whether RVM KOR modulates affective versus sensory pain dimensions was not addressed"]},{"year":2008,"claim":"A functional insertion/deletion variant upstream of the OPRK1 coding region was shown to halve transcriptional activity, providing the first direct evidence that cis-regulatory variation modulates KOR expression levels.","evidence":"Luciferase reporter promoter assays with allele-specific constructs","pmids":["18319328"],"confidence":"High","gaps":["Effect on endogenous KOR protein levels in human tissue not demonstrated","Association with addiction phenotypes was suggestive but not definitive"]},{"year":2011,"claim":"Development and validation of phospho-Ser369-specific antibodies confirmed that GRK-mediated phosphorylation of KOR's C-terminal tail is an in vivo marker of receptor activation, linking agonist exposure and stress to a defined post-translational modification.","evidence":"Phospho-selective antibody immunohistochemistry following behavioral and pharmacological manipulation in rodents","pmids":["21370032"],"confidence":"Medium","gaps":["Contribution of specific GRK isoforms was not determined","Downstream consequences of Ser369 phosphorylation beyond β-arrestin recruitment were not dissected"]},{"year":2012,"claim":"Demonstration that KOR on macrophages signals through ERK1/2 upon dynorphin-A stimulation, with IFN-γ upregulating KOR expression, extended KOR function beyond neurons to immune cells.","evidence":"Western blot for phospho-ERK1/2 in J774 macrophages stimulated with Dynorphin-A(1-17) vs. truncated control","pmids":["22424981"],"confidence":"Medium","gaps":["Physiological relevance of macrophage KOR signaling in vivo not established","Whether ERK activation leads to cytokine modulation was not tested"]},{"year":2015,"claim":"Three advances refined KOR biology: crystal structures of inactive (JDTic-bound) KOR revealed subtype selectivity determinants; CpG methylation of the OPRK1 promoter was shown to suppress transcription; and KOR-Cre knockin mice mapped KOR expression across brain regions and peripheral tissues from embryonic day 14.5.","evidence":"X-ray crystallography; luciferase reporter assay with bisulphite pyrosequencing; Cre-reporter recombination mapping in knockin mice","pmids":["33945028","26300544","26575788","26160155"],"confidence":"High","gaps":["Active-state KOR structure dynamics and G protein coupling interface not fully resolved at this time","Functional consequences of KOR expression in non-neuronal tissues remain largely unexplored"]},{"year":2020,"claim":"Intra-VTA KOR blockade attenuated real-time dopamine decreases and avoidance behavior, placing VTA KOR upstream of striatal dopamine signaling in aversion-driven learned avoidance and defining a circuit mechanism for KOR-mediated dysphoria.","evidence":"Site-specific norBNI infusion with fast-scan cyclic voltammetry for dopamine and behavioral avoidance assay in rats","pmids":["32057802"],"confidence":"High","gaps":["Cell-type specificity of VTA KOR (dopaminergic vs. GABAergic neurons) was not resolved","Whether this circuit mediates stress-induced relapse to drug seeking was not directly tested"]},{"year":2021,"claim":"Knockin mice lacking four C-terminal KOR phosphorylation sites revealed that receptor phosphorylation mediates tolerance and conditioned place aversion in a sex-dependent manner, dissociating phosphorylation-dependent from phosphorylation-independent behavioral outputs.","evidence":"K4A knockin mice with behavioral pharmacology (anti-scratch tolerance, conditioned place aversion, locomotion)","pmids":["34736959"],"confidence":"High","gaps":["Molecular basis for the sex difference (hormonal vs. circuit) was not identified","Which of the four residues is most critical was not resolved"]},{"year":2022,"claim":"Multiple studies in 2022 expanded the KOR signaling repertoire: AC3 was identified as essential for peripheral KOR/Gαi-o coupling to Kv channels and analgesia; dynorphin/KOR was shown to inhibit autophagy via mTOR; KOR overexpression in VTA DA neurons recapitulated alcohol dependence phenotypes; and central vs. peripheral KOR pathways were pharmacologically dissected for diuresis vs. electrolyte handling.","evidence":"AC3 conditional KO with electrophysiology; prodynorphin overexpression with rapamycin rescue in epilepsy models; Cre-Lox Oprk1 overexpression in TH::Cre rats; ICV vs. IV norBNI with renal function readouts","pmids":["34914639","35989483","36764577","36202183"],"confidence":"High","gaps":["Whether AC3-KOR interaction is direct or scaffolded remains unclear","mTOR pathway activation by KOR needs confirmation beyond epilepsy context","How VTA KOR overexpression interacts with endogenous dynorphin tone is unknown"]},{"year":2023,"claim":"Post-transcriptional regulation of OPRK1 by miR-144-3p was validated, and KOR's circuit-level role in pain-aversive memory was placed upstream of insular cortex GABAergic neurons, while KOR/STAT3 signaling was linked to oligodendrocyte precursor cell maturation and remyelination.","evidence":"Luciferase 3′UTR reporter assay for miR-144-3p; DREADD chemogenetics with intra-insular KOR pharmacology; virtual screening with in vitro OPC differentiation and in vivo demyelination models","pmids":["37455648","37679857","38692525"],"confidence":"Medium","gaps":["miR-144-3p regulation of OPRK1 not confirmed in human tissue","KOR/STAT3 pathway in remyelination demonstrated with repurposed drug (famotidine) whose selectivity for KOR over H2R in vivo needs clarification","Insular cortex findings are from a single pain model"]},{"year":null,"claim":"Key unresolved questions include the structural basis of biased agonism at KOR (G protein vs. β-arrestin pathways), the molecular determinants of sex-dependent KOR phosphorylation effects, the physiological roles of KOR in non-neuronal tissues identified by expression mapping, and whether KOR-targeted therapies can achieve pathway-selective efficacy in humans.","evidence":"","pmids":[],"confidence":"Low","gaps":["No human clinical validation of biased KOR agonism for dissociating therapeutic from adverse effects","Structural basis for agonist-induced conformational bias at KOR not resolved at atomic level","KOR function in peripheral immune and epithelial cells remains largely unexplored mechanistically"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[5,7,8,9]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,19]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[5,6,9]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[5]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,4,5,8,10,19]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[8,11,16,18]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[19]}],"complexes":[],"partners":["ADCY3","GRK3","ARRB2","PDYN","STAT3","MTOR"],"other_free_text":[]},"mechanistic_narrative":"OPRK1 encodes the kappa opioid receptor (KOR), a Gαi/o-coupled GPCR activated by dynorphin peptides and selective synthetic agonists such as U50,488H that functions as a central modulator of nociception, aversion, reward, and affective behavior. KOR activation inhibits cAMP production — requiring adenylyl cyclase 3 in peripheral sensory neurons — and engages downstream ERK1/2, p38 MAPK, mTOR, and STAT3 signaling pathways; agonist-stimulated GRK phosphorylation at C-terminal residues (including Ser369) initiates β-arrestin-dependent desensitization, with phosphorylation-site mutations revealing sex-dependent roles in tolerance and conditioned place aversion [PMID:34736959, PMID:21370032, PMID:34914639, PMID:22424981]. Within the mesolimbic dopamine system, VTA KOR activation suppresses striatal dopamine release to drive aversive learning and avoidance behavior, and cell-type-specific KOR overexpression in VTA dopaminergic neurons is sufficient to escalate alcohol self-administration and produce depressive-like phenotypes [PMID:32057802, PMID:36764577]. OPRK1 transcription is repressed by a functional promoter insertion/deletion variant and by CpG methylation, and post-transcriptionally suppressed by miR-144-3p targeting the 3′UTR [PMID:18319328, PMID:26300544, PMID:37455648]."},"prefetch_data":{"uniprot":{"accession":"P41145","full_name":"Kappa-type opioid receptor","aliases":[],"length_aa":380,"mass_kda":42.6,"function":"G-protein coupled opioid receptor that functions as a receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as a receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurotransmitter release by reducing calcium ion currents and increasing potassium ion conductance. Plays a role in the perception of pain. Plays a role in mediating reduced physical activity upon treatment with synthetic opioids. Plays a role in the regulation of salivation in response to synthetic opioids. May play a role in arousal and regulation of autonomic and neuroendocrine functions","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P41145/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/OPRK1","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/OPRK1","total_profiled":1310},"omim":[{"mim_id":"613098","title":"INCREASED ANALGESIA FROM KAPPA-OPIOID RECEPTOR AGONIST, FEMALE-SPECIFIC","url":"https://www.omim.org/entry/613098"},{"mim_id":"600731","title":"G PROTEIN-COUPLED RECEPTOR 8; GPR8","url":"https://www.omim.org/entry/600731"},{"mim_id":"600730","title":"NEUROPEPTIDES B AND W RECEPTOR 1; NPBWR1","url":"https://www.omim.org/entry/600730"},{"mim_id":"600018","title":"OPIOID RECEPTOR, MU-1; OPRM1","url":"https://www.omim.org/entry/600018"},{"mim_id":"300005","title":"METHYL-CpG-BINDING PROTEIN 2; MECP2","url":"https://www.omim.org/entry/300005"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":3.8},{"tissue":"prostate","ntpm":1.5}],"url":"https://www.proteinatlas.org/search/OPRK1"},"hgnc":{"alias_symbol":["KOR","OPRK"],"prev_symbol":[]},"alphafold":{"accession":"P41145","domains":[{"cath_id":"1.20.1070.10","chopping":"79-123_135-189_235-258_269-346","consensus_level":"high","plddt":90.0736,"start":79,"end":346}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P41145","model_url":"https://alphafold.ebi.ac.uk/files/AF-P41145-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P41145-F1-predicted_aligned_error_v6.png","plddt_mean":79.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=OPRK1","jax_strain_url":"https://www.jax.org/strain/search?query=OPRK1"},"sequence":{"accession":"P41145","fasta_url":"https://rest.uniprot.org/uniprotkb/P41145.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P41145/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P41145"}},"corpus_meta":[{"pmid":"17374034","id":"PMC_17374034","title":"Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.","date":"2007","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/17374034","citation_count":171,"is_preprint":false},{"pmid":"15608558","id":"PMC_15608558","title":"Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction.","date":"2004","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/15608558","citation_count":83,"is_preprint":false},{"pmid":"6308390","id":"PMC_6308390","title":"Deletion mapping of kil and kor functions in the trfA and trfB regions of broad host range plasmid RK2.","date":"1983","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/6308390","citation_count":75,"is_preprint":false},{"pmid":"3891728","id":"PMC_3891728","title":"Replication control in promiscuous plasmid RK2: kil and kor functions affect expression of the essential replication gene trfA.","date":"1985","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/3891728","citation_count":69,"is_preprint":false},{"pmid":"8585747","id":"PMC_8585747","title":"The outer membrane protein OprM of Pseudomonas aeruginosa is encoded by oprK of the mexA-mexB-oprK multidrug resistance operon.","date":"1995","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/8585747","citation_count":67,"is_preprint":false},{"pmid":"3040681","id":"PMC_3040681","title":"Plasmid transfer in Streptomyces lividans: identification of a kil-kor system associated with the transfer region of pIJ101.","date":"1987","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/3040681","citation_count":67,"is_preprint":false},{"pmid":"17005613","id":"PMC_17005613","title":"Kappa opioid receptor (KOR) and GAD67 immunoreactivity are found in OFF and NEUTRAL cells in the rostral ventromedial medulla.","date":"2006","source":"Journal of neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/17005613","citation_count":63,"is_preprint":false},{"pmid":"17373729","id":"PMC_17373729","title":"Human kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction.","date":"2007","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17373729","citation_count":60,"is_preprint":false},{"pmid":"2681140","id":"PMC_2681140","title":"Identification and analysis of transcriptional regulatory signals for the kil and kor loci of Streptomyces plasmid pIJ101.","date":"1989","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2681140","citation_count":60,"is_preprint":false},{"pmid":"8366038","id":"PMC_8366038","title":"Transfer functions of the conjugative integrating element pSAM2 from Streptomyces ambofaciens: characterization of a kil-kor system associated with transfer.","date":"1993","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/8366038","citation_count":52,"is_preprint":false},{"pmid":"18319328","id":"PMC_18319328","title":"A regulatory variation in OPRK1, the gene encoding the kappa-opioid receptor, is associated with alcohol dependence.","date":"2008","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18319328","citation_count":51,"is_preprint":false},{"pmid":"35069503","id":"PMC_35069503","title":"Major Bloodstream Infection-Causing Bacterial Pathogens and Their Antimicrobial Resistance in South Korea, 2017-2019: Phase I Report From Kor-GLASS.","date":"2022","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/35069503","citation_count":50,"is_preprint":false},{"pmid":"8585714","id":"PMC_8585714","title":"OprK and OprM define two genetically distinct multidrug efflux systems in Pseudomonas aeruginosa.","date":"1995","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/8585714","citation_count":48,"is_preprint":false},{"pmid":"15287736","id":"PMC_15287736","title":"Recombinant expression and enzymatic characterization of PttCel9A, a KOR homologue from Populus tremula x tremuloides.","date":"2004","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15287736","citation_count":45,"is_preprint":false},{"pmid":"23962922","id":"PMC_23962922","title":"A variant on the kappa opioid receptor gene (OPRK1) is associated with stress response and related drug craving, limbic brain activation and cocaine relapse risk.","date":"2013","source":"Translational psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/23962922","citation_count":45,"is_preprint":false},{"pmid":"30707578","id":"PMC_30707578","title":"Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140).","date":"2019","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30707578","citation_count":42,"is_preprint":false},{"pmid":"9755860","id":"PMC_9755860","title":"Identification and differential regional expression of KOR-3/ORL-1 gene splice variants in mouse brain.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9755860","citation_count":40,"is_preprint":false},{"pmid":"27567942","id":"PMC_27567942","title":"Involvement of the dynorphin/KOR system on the nociceptive, emotional and cognitive manifestations of joint pain in mice.","date":"2016","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27567942","citation_count":34,"is_preprint":false},{"pmid":"7543176","id":"PMC_7543176","title":"A novel monoclonal antibody, KOR-SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukemia cells with high sensitivity.","date":"1995","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/7543176","citation_count":31,"is_preprint":false},{"pmid":"20651463","id":"PMC_20651463","title":"Chicken collagen hydrolysate reduces proinflammatory cytokine production in C57BL/6.KOR-ApoEshl mice.","date":"2010","source":"Journal of nutritional science and vitaminology","url":"https://pubmed.ncbi.nlm.nih.gov/20651463","citation_count":31,"is_preprint":false},{"pmid":"2160936","id":"PMC_2160936","title":"The kil-kor regulon of broad-host-range plasmid RK2: nucleotide sequence, polypeptide product, and expression of regulatory gene korC.","date":"1990","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/2160936","citation_count":29,"is_preprint":false},{"pmid":"26785295","id":"PMC_26785295","title":"Synthesis of mixed MOR/KOR efficacy cyclic opioid peptide analogs with antinociceptive activity after systemic administration.","date":"2015","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26785295","citation_count":27,"is_preprint":false},{"pmid":"22097957","id":"PMC_22097957","title":"Oral infection with Porphyromonas gingivalis and systemic cytokine profile in C57BL/6.KOR-ApoE shl mice.","date":"2011","source":"Journal of periodontal research","url":"https://pubmed.ncbi.nlm.nih.gov/22097957","citation_count":27,"is_preprint":false},{"pmid":"26300544","id":"PMC_26300544","title":"OPRK1 promoter hypermethylation increases the risk of Alzheimer's disease.","date":"2015","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/26300544","citation_count":27,"is_preprint":false},{"pmid":"33834276","id":"PMC_33834276","title":"Preclinical Studies on Nalfurafine (TRK-820), a Clinically Used KOR Agonist.","date":"2022","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33834276","citation_count":26,"is_preprint":false},{"pmid":"9665191","id":"PMC_9665191","title":"Aberrant expression of KOR-SA3544 antigen in childhood acute lymphoblastic leukemia predicts TEL-AML1 negativity. The Pediatric Hematology Working Group in the Czech Republic.","date":"1998","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9665191","citation_count":26,"is_preprint":false},{"pmid":"8349548","id":"PMC_8349548","title":"kil-kor regulon of promiscuous plasmid RK2: structure, products, and regulation of two operons that constitute the kilE locus.","date":"1993","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/8349548","citation_count":26,"is_preprint":false},{"pmid":"26160155","id":"PMC_26160155","title":"Characterization of kappa opioid receptor mediated, dynorphin-stimulated [35S]GTPγS binding in mouse striatum for the evaluation of selective KOR ligands in an endogenous setting.","date":"2015","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26160155","citation_count":26,"is_preprint":false},{"pmid":"6097793","id":"PMC_6097793","title":"Involvement of kil and kor genes in the phenotype of a host-range mutant of RP4.","date":"1984","source":"Molecular & general genetics : MGG","url":"https://pubmed.ncbi.nlm.nih.gov/6097793","citation_count":24,"is_preprint":false},{"pmid":"25996309","id":"PMC_25996309","title":"Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors.","date":"2015","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25996309","citation_count":24,"is_preprint":false},{"pmid":"26575788","id":"PMC_26575788","title":"Generation of a KOR-Cre knockin mouse strain to study cells involved in kappa opioid signaling.","date":"2015","source":"Genesis (New York, N.Y. : 2000)","url":"https://pubmed.ncbi.nlm.nih.gov/26575788","citation_count":23,"is_preprint":false},{"pmid":"33301050","id":"PMC_33301050","title":"KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway.","date":"2022","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33301050","citation_count":21,"is_preprint":false},{"pmid":"10374883","id":"PMC_10374883","title":"The KOR-SA3544 antigen predominantly expressed on the surface of Philadelphia chromosome-positive acute lymphoblastic leukemia cells is nonspecific cross-reacting antigen-50/90 (CD66c) and invariably expressed in cytoplasm of human leukemia cells.","date":"1999","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/10374883","citation_count":20,"is_preprint":false},{"pmid":"22424981","id":"PMC_22424981","title":"IFN-γ up-regulates κ opioid receptors (KOR) on murine macrophage cell line J774.","date":"2012","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/22424981","citation_count":19,"is_preprint":false},{"pmid":"18838807","id":"PMC_18838807","title":"Hypolipidemic effect of young persimmon fruit in C57BL/6.KOR-ApoEshl mice.","date":"2008","source":"Bioscience, biotechnology, and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18838807","citation_count":19,"is_preprint":false},{"pmid":"28786760","id":"PMC_28786760","title":"Association of OPRK1 gene polymorphisms with opioid dependence in addicted men undergoing methadone treatment in an Iranian population.","date":"2017","source":"Journal of addictive diseases","url":"https://pubmed.ncbi.nlm.nih.gov/28786760","citation_count":18,"is_preprint":false},{"pmid":"35900351","id":"PMC_35900351","title":"SLL-627 Is a Highly Selective and Potent κ Opioid Receptor (KOR) Agonist with an Unexpected Nonreduction in Locomotor Activity.","date":"2022","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/35900351","citation_count":17,"is_preprint":false},{"pmid":"15023399","id":"PMC_15023399","title":"Effect of n-3 fatty acids on serum lipid levels and hepatic fatty acid metabolism in BALB/c.KOR-Apoeshl mice deficient in apolipoprotein E expression.","date":"2004","source":"The Journal of nutritional biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15023399","citation_count":17,"is_preprint":false},{"pmid":"26907190","id":"PMC_26907190","title":"Highly selective non-opioid kappa opioid receptor (KOR) agonist salvinorin A protects against forebrain ischemia-induced brain injury in rats.","date":"2016","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/26907190","citation_count":17,"is_preprint":false},{"pmid":"32435819","id":"PMC_32435819","title":"Modulation of cocaine-related behaviors by low doses of the potent KOR agonist nalfurafine in male C57BL6 mice.","date":"2020","source":"Psychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32435819","citation_count":17,"is_preprint":false},{"pmid":"27262683","id":"PMC_27262683","title":"CB1 receptor antagonism prevents long-term hyperexcitability after head injury by regulation of dynorphin-KOR system and mGluR5 in rat hippocampus.","date":"2016","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/27262683","citation_count":16,"is_preprint":false},{"pmid":"36294562","id":"PMC_36294562","title":"Nationwide Surveillance of Antifungal Resistance of Candida Bloodstream Isolates in South Korean Hospitals: Two Year Report from Kor-GLASS.","date":"2022","source":"Journal of fungi (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/36294562","citation_count":16,"is_preprint":false},{"pmid":"32808003","id":"PMC_32808003","title":"Chemical syntheses of the salvinorin chemotype of KOR agonist.","date":"2020","source":"Natural product reports","url":"https://pubmed.ncbi.nlm.nih.gov/32808003","citation_count":15,"is_preprint":false},{"pmid":"32057802","id":"PMC_32057802","title":"Learned avoidance requires VTA KOR-mediated reductions in dopamine.","date":"2020","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32057802","citation_count":15,"is_preprint":false},{"pmid":"34443366","id":"PMC_34443366","title":"In Silico Identification of Tripeptides as Lead Compounds for the Design of KOR Ligands.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34443366","citation_count":14,"is_preprint":false},{"pmid":"29623611","id":"PMC_29623611","title":"m-Trifluoromethyl-diphenyl Diselenide Regulates Prefrontal Cortical MOR and KOR Protein Levels and Abolishes the Phenotype Induced by Repeated Forced Swim Stress in Mice.","date":"2018","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29623611","citation_count":14,"is_preprint":false},{"pmid":"34736959","id":"PMC_34736959","title":"Agonist-promoted kappa opioid receptor (KOR) phosphorylation has behavioral endpoint-dependent and sex-specific effects.","date":"2021","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34736959","citation_count":13,"is_preprint":false},{"pmid":"36924727","id":"PMC_36924727","title":"Machine-learning analysis of opioid use disorder informed by MOR, DOR, KOR, NOR and ZOR-based interactome networks.","date":"2023","source":"Computers in biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36924727","citation_count":13,"is_preprint":false},{"pmid":"26949961","id":"PMC_26949961","title":"Isolation and Characterization of a New Methanobacterium formicicum KOR-1 from an Anaerobic Digester Using Pig Slurry.","date":"2016","source":"Asian-Australasian journal of animal sciences","url":"https://pubmed.ncbi.nlm.nih.gov/26949961","citation_count":13,"is_preprint":false},{"pmid":"1852017","id":"PMC_1852017","title":"Differentiation of lethal and nonlethal, kor-regulated functions in the kilB region of broad host-range plasmid RK2.","date":"1991","source":"Plasmid","url":"https://pubmed.ncbi.nlm.nih.gov/1852017","citation_count":13,"is_preprint":false},{"pmid":"11247609","id":"PMC_11247609","title":"Expression of a membrane-anchored endo-1,4-beta-glucanase from Brassica napus, orthologous to KOR from Arabidopsis thaliana, is inversely correlated to elongation in light-grown plants.","date":"2001","source":"Plant molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11247609","citation_count":13,"is_preprint":false},{"pmid":"10224306","id":"PMC_10224306","title":"Antisense mapping KOR-1: evidence for multiple kappa analgesic mechanisms.","date":"1999","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/10224306","citation_count":13,"is_preprint":false},{"pmid":"21370032","id":"PMC_21370032","title":"Signaling events initiated by kappa opioid receptor activation: quantification and immunocolocalization using phospho-selective KOR, p38 MAPK, and K(IR) 3.1 antibodies.","date":"2011","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/21370032","citation_count":13,"is_preprint":false},{"pmid":"27838450","id":"PMC_27838450","title":"Association of OPRK1 and OPRM1 methylation with mild cognitive impairment in Xinjiang Han and Uygur populations.","date":"2016","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/27838450","citation_count":12,"is_preprint":false},{"pmid":"34914639","id":"PMC_34914639","title":"Peripheral ablation of type III adenylyl cyclase induces hyperalgesia and eliminates KOR-mediated analgesia in mice.","date":"2022","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/34914639","citation_count":12,"is_preprint":false},{"pmid":"29426768","id":"PMC_29426768","title":"O6C-20-nor-salvinorin A is a stable and potent KOR agonist.","date":"2018","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/29426768","citation_count":12,"is_preprint":false},{"pmid":"27269866","id":"PMC_27269866","title":"6β-N-Heterocyclic Substituted Naltrexamine Derivative BNAP: A Peripherally Selective Mixed MOR/KOR Ligand.","date":"2016","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27269866","citation_count":12,"is_preprint":false},{"pmid":"28745376","id":"PMC_28745376","title":"Stereoselective synthesis of conformationally restricted KOR agonists based on the 2,5-diazabicyclo[2.2.2]octane scaffold.","date":"2017","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28745376","citation_count":12,"is_preprint":false},{"pmid":"28242307","id":"PMC_28242307","title":"Molecular identification of the Dyn/Kor system and its potential role in the reproductive axis of goldfish.","date":"2017","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28242307","citation_count":11,"is_preprint":false},{"pmid":"37679857","id":"PMC_37679857","title":"Electroacupuncture alleviates the relapse of pain-related aversive memory by activating KOR and inhibiting GABAergic neurons in the insular cortex.","date":"2023","source":"Cerebral cortex (New York, N.Y. : 1991)","url":"https://pubmed.ncbi.nlm.nih.gov/37679857","citation_count":10,"is_preprint":false},{"pmid":"33448685","id":"PMC_33448685","title":"Synthesis and Pharmacological Evaluation of Fluorinated Quinoxaline-Based κ-Opioid Receptor (KOR) Agonists Designed for PET Studies.","date":"2020","source":"ChemMedChem","url":"https://pubmed.ncbi.nlm.nih.gov/33448685","citation_count":9,"is_preprint":false},{"pmid":"36260530","id":"PMC_36260530","title":"Conditional Deletion of KOR (Oprk1) in Kisspeptin Cells Does Not Alter LH Pulses, Puberty, or Fertility in Mice.","date":"2022","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36260530","citation_count":9,"is_preprint":false},{"pmid":"25147605","id":"PMC_25147605","title":"Synthesis and Pharmacology of a Novel κ Opioid Receptor (KOR) Agonist with a 1,3,5-Trioxazatriquinane Skeleton.","date":"2014","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/25147605","citation_count":9,"is_preprint":false},{"pmid":"37708692","id":"PMC_37708692","title":"Activation of kappa opioid receptor (KOR) inhibits estrogen receptor (ER)-positive breast cancer through the KOR-ER-XBP1 pathway.","date":"2023","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/37708692","citation_count":9,"is_preprint":false},{"pmid":"34852633","id":"PMC_34852633","title":"Nalfurafine, a G-Protein-Biased KOR (Kappa Opioid Receptor) Agonist, Enhances the Diuretic Response and Limits Electrolyte Losses to Standard-of-Care Diuretics.","date":"2021","source":"Hypertension (Dallas, Tex. : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/34852633","citation_count":9,"is_preprint":false},{"pmid":"35989483","id":"PMC_35989483","title":"Dynorphin/KOR inhibits neuronal autophagy by activating mTOR signaling pathway to prevent acute seizure epilepsy.","date":"2022","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/35989483","citation_count":8,"is_preprint":false},{"pmid":"36385929","id":"PMC_36385929","title":"Discovery of κ Opioid Receptor (KOR)-Selective d-Tetrapeptides with Improved In Vivo Antinociceptive Effect after Peripheral Administration.","date":"2022","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/36385929","citation_count":8,"is_preprint":false},{"pmid":"36449691","id":"PMC_36449691","title":"Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine Analogues.","date":"2022","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36449691","citation_count":8,"is_preprint":false},{"pmid":"15121216","id":"PMC_15121216","title":"Opposite alterations of NPFF1 and NPFF2 neuropeptide FF receptor density in the triple MOR/DOR/KOR-opioid receptor knockout mouse brains.","date":"2004","source":"Journal of chemical neuroanatomy","url":"https://pubmed.ncbi.nlm.nih.gov/15121216","citation_count":8,"is_preprint":false},{"pmid":"36764577","id":"PMC_36764577","title":"Recapitulating phenotypes of alcohol dependence via overexpression of Oprk1 in the ventral tegmental area of non-dependent TH::Cre rats.","date":"2023","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36764577","citation_count":7,"is_preprint":false},{"pmid":"34072734","id":"PMC_34072734","title":"Multifunctional Enkephalin Analogs with a New Biological Profile: MOR/DOR Agonism and KOR Antagonism.","date":"2021","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/34072734","citation_count":7,"is_preprint":false},{"pmid":"34528988","id":"PMC_34528988","title":"Synthesis and pharmacological evaluation of enantiomerically pure endo-configured KOR agonists with 2-azabicyclo[3.2.1]octane scaffold.","date":"2021","source":"Organic & biomolecular chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34528988","citation_count":7,"is_preprint":false},{"pmid":"28111440","id":"PMC_28111440","title":"Isolation and characterization of new Methanosarcina mazei strains KOR-3, -4, -5, and -6 from an anaerobic digester using pig slurry.","date":"2017","source":"Asian-Australasian journal of animal sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28111440","citation_count":7,"is_preprint":false},{"pmid":"24405578","id":"PMC_24405578","title":"Neurocognitive and neuroinflammatory correlates of PDYN and OPRK1 mRNA expression in the anterior cingulate in postmortem brain of HIV-infected subjects.","date":"2014","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/24405578","citation_count":7,"is_preprint":false},{"pmid":"34843875","id":"PMC_34843875","title":"Analyses of polymorphisms of intron 2 of OPRK1 (kappa-opioid receptor gene) in association with opioid and cocaine dependence diagnoses in an African-American population.","date":"2021","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/34843875","citation_count":7,"is_preprint":false},{"pmid":"30056662","id":"PMC_30056662","title":"Isolation and characterization of a new Methanoculleus bourgensis strain KOR-2 from the rumen of Holstein steers.","date":"2018","source":"Asian-Australasian journal of animal sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30056662","citation_count":6,"is_preprint":false},{"pmid":"25177835","id":"PMC_25177835","title":"A molecular prospective provides new insights into implication of PDYN and OPRK1 genes in alcohol dependence.","date":"2014","source":"Computers in biology and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25177835","citation_count":6,"is_preprint":false},{"pmid":"37177778","id":"PMC_37177778","title":"Effect of PDYN and OPRK1 polymorphisms on the risk of alcohol use disorder and the intensity of depressive symptoms.","date":"2023","source":"Alcohol and alcoholism (Oxford, Oxfordshire)","url":"https://pubmed.ncbi.nlm.nih.gov/37177778","citation_count":5,"is_preprint":false},{"pmid":"37455648","id":"PMC_37455648","title":"The role of miRNA-144-3p/Oprk1/KOR in nicotine dependence and nicotine withdrawal in male rats.","date":"2023","source":"Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco","url":"https://pubmed.ncbi.nlm.nih.gov/37455648","citation_count":4,"is_preprint":false},{"pmid":"30365572","id":"PMC_30365572","title":"Genetic Variations of OPRM1, OPRK1, and COMT Genes and Their Possible Associations with Oral Pain in a Population from Argentina.","date":"2018","source":"Journal of oral & facial pain and headache","url":"https://pubmed.ncbi.nlm.nih.gov/30365572","citation_count":4,"is_preprint":false},{"pmid":"38862675","id":"PMC_38862675","title":"Differential methylation of OPRK1 in borderline personality disorder is associated with childhood trauma.","date":"2024","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/38862675","citation_count":4,"is_preprint":false},{"pmid":"31556948","id":"PMC_31556948","title":"Effects of the Alpha-1 Antagonist Prazosin on KOR Agonist-Induced Reinstatement of Alcohol Seeking.","date":"2019","source":"The international journal of neuropsychopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31556948","citation_count":4,"is_preprint":false},{"pmid":"36202183","id":"PMC_36202183","title":"Difelikefalin, a peripherally restricted KOR (kappa opioid receptor) agonist, produces diuresis through a central KOR pathway.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/36202183","citation_count":4,"is_preprint":false},{"pmid":"21069260","id":"PMC_21069260","title":"Evaluation of the effect of flavangenol on serum lipid peroxide levels and development of atherosclerosis in spontaneously hyperlipidemic B6.KOR-Apoeshl mice.","date":"2010","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21069260","citation_count":4,"is_preprint":false},{"pmid":"38692525","id":"PMC_38692525","title":"Targeting of KOR by famotidine promotes OPC maturation differentiation and CNS remyelination via STAT3 signaling pathway.","date":"2024","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/38692525","citation_count":3,"is_preprint":false},{"pmid":"40588011","id":"PMC_40588011","title":"KOR agonists for the treatment and/or prevention of opioid use disorder and cocaine use disorder.","date":"2025","source":"Pharmacology, biochemistry, and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/40588011","citation_count":3,"is_preprint":false},{"pmid":"27843991","id":"PMC_27843991","title":"Karyological and molecular analysis of three endemic loaches (Actinopterygii: Cobitoidea) from Kor River basin, Iran.","date":"2015","source":"Molecular biology research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27843991","citation_count":3,"is_preprint":false},{"pmid":"37396111","id":"PMC_37396111","title":"Comprehensive behavioral study of C57BL/6.KOR-ApoEshl mice.","date":"2023","source":"Translational neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37396111","citation_count":2,"is_preprint":false},{"pmid":"33945028","id":"PMC_33945028","title":"Structural Characterization of KOR Inactive and Active States for 3D Pharmacology and Drug Discovery.","date":"2022","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33945028","citation_count":2,"is_preprint":false},{"pmid":"37166316","id":"PMC_37166316","title":"Association of OPRK1 rs963549 and rs997917 polymorphisms with opioid use disorder and related phenotypes.","date":"2023","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/37166316","citation_count":2,"is_preprint":false},{"pmid":"34731743","id":"PMC_34731743","title":"Estimation of ZYKR1 in human urine and plasma utilizing LC-MS/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist.","date":"2021","source":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34731743","citation_count":2,"is_preprint":false},{"pmid":"22771010","id":"PMC_22771010","title":"An efficient synthesis of 3-OBn-6β,14-epoxy-bridged opiates from naltrexone and identification of a related dual MOR inverse agonist/KOR agonist.","date":"2012","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/22771010","citation_count":2,"is_preprint":false},{"pmid":"36695971","id":"PMC_36695971","title":"Clustering of KOR PET images separates people with AUD into distinct responses to naltrexone.","date":"2023","source":"Brain imaging and behavior","url":"https://pubmed.ncbi.nlm.nih.gov/36695971","citation_count":2,"is_preprint":false},{"pmid":"38986343","id":"PMC_38986343","title":"Discovery of N'-benzyl-3-chloro-N-((1S,3R,4R)-3-((dimethylamino)methyl)-4-hydroxy-4-(3-methoxyphenyl)cyclohexyl)benzenesulfonamide as a novel selective KOR ligand.","date":"2024","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/38986343","citation_count":2,"is_preprint":false},{"pmid":"40068406","id":"PMC_40068406","title":"Structure-activity relationship analysis of meta-substituted N-cyclopropylmethyl-nornepenthones with mixed KOR/MOR activities.","date":"2025","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40068406","citation_count":2,"is_preprint":false},{"pmid":"40633208","id":"PMC_40633208","title":"U50 488H KOR agonist reduces cartilage degradation, chondrocyte hypertrophy and bone loss in osteoarthritis.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40633208","citation_count":2,"is_preprint":false},{"pmid":"38893511","id":"PMC_38893511","title":"Decoding the κ Opioid Receptor (KOR): Advancements in Structural Understanding and Implications for Opioid Analgesic Development.","date":"2024","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38893511","citation_count":1,"is_preprint":false},{"pmid":"38147391","id":"PMC_38147391","title":"[Polymorphisms of OPRM1, OPRK1, DCC genes and non-suicidal self-injuries in adults].","date":"2023","source":"Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova","url":"https://pubmed.ncbi.nlm.nih.gov/38147391","citation_count":1,"is_preprint":false},{"pmid":"40567495","id":"PMC_40567495","title":"The efficacy and safety of kappa opioid receptor (KOR) agonists in patients with uraemic pruritus: a systematic review and network meta-analysis.","date":"2025","source":"Clinical kidney journal","url":"https://pubmed.ncbi.nlm.nih.gov/40567495","citation_count":1,"is_preprint":false},{"pmid":"40027836","id":"PMC_40027836","title":"Triazole 187 is a biased KOR agonist that suppresses itch without sedation and induces anxiolytic-like behaviors in mice.","date":"2025","source":"bioRxiv : the preprint server for biology","url":"https://pubmed.ncbi.nlm.nih.gov/40027836","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51077,"output_tokens":5292,"usd":0.116306},"stage2":{"model":"claude-opus-4-6","input_tokens":8827,"output_tokens":2931,"usd":0.176115},"total_usd":0.292421,"stage1_batch_id":"msgbatch_012ZiiCUBfB62NCTQd4Bk1Jo","stage2_batch_id":"msgbatch_01Xuqq9aUHoQouS7UVGZNStZ","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2008,\n      \"finding\": \"An insertion/deletion variant located ~1986 bp upstream of the OPRK1 translation start site functions as a regulatory element; the longer allele (with the indel) reduced OPRK1 transcriptional activity by approximately half in transient transfection promoter assays, establishing this as a functional regulatory variation affecting KOR expression levels.\",\n      \"method\": \"Transient transfection promoter assay (luciferase reporter), PCR genotyping, family-based association analysis\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro promoter/reporter assay demonstrating functional consequence of the variant on transcription\",\n      \"pmids\": [\"18319328\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"OPRK1 promoter hypermethylation reduces OPRK1 gene expression; luciferase reporter assay demonstrated that a CpG-containing fragment of the OPRK1 promoter significantly increased reporter gene expression (~2.25-fold), indicating that methylation of this region suppresses KOR expression.\",\n      \"method\": \"Bisulphite pyrosequencing for methylation quantification; luciferase reporter gene assay\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 reporter assay but single lab, single paper with moderate methods\",\n      \"pmids\": [\"26300544\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"KOR (encoded by OPRK1) is phosphorylated at Ser369 in its C-terminal tail by G protein receptor kinase (GRK) upon agonist activation, initiating the β-arrestin-dependent desensitization cascade; phospho-selective antibodies against this site were developed and validated to track KOR activation in vivo following stress or behavioral stimuli.\",\n      \"method\": \"Phospho-selective antibody development and immunohistochemical validation; behavioral and pharmacological manipulation in rodents\",\n      \"journal\": \"Methods in molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — phospho-specific antibody validated against defined site, single lab\",\n      \"pmids\": [\"21370032\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Agonist-promoted phosphorylation of mouse KOR at four C-terminal residues (mutated to Ala in K4A mice) plays sex-dependent roles in tolerance and conditioned place aversion (CPA): male K4A mice showed attenuated tolerance to anti-scratch effects and retained CPA to U50,488H, while female K4A mice showed no CPA, revealing that KOR phosphorylation mediates behavioral endpoints in a sex-specific manner without affecting acute anti-pruritic or hypo-locomotor effects.\",\n      \"method\": \"Knockin mouse (K4A mutant), autoradiography ([3H]U69,593 binding), behavioral assays (scratch, locomotion, conditioned place aversion, tolerance), in vivo pharmacology\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vivo genetic mutagenesis of phosphorylation sites with multiple defined behavioral readouts, validated receptor expression\",\n      \"pmids\": [\"34736959\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Peripheral conditional knockout of adenylyl cyclase 3 (AC3) in DRGs eliminated the analgesic effect of a KOR agonist and blocked KOR-mediated inhibition of voltage-gated potassium (Kv) channels, demonstrating that AC3 is required for KOR/Gαi-o signaling and possibly via direct KOR-AC3 protein interaction in peripheral sensory neurons.\",\n      \"method\": \"Conditional KO (AC3 CKO in L3/L4 DRGs), Kv channel current recordings, cAMP measurements, behavioral nociception assays, Western blot, pharmacological rescue\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — genetic KO with electrophysiology, biochemistry, and behavioral validation across multiple orthogonal approaches\",\n      \"pmids\": [\"34914639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"KOR expressed on murine macrophage J774 cells is functionally active: ligation with Dynorphin-A(1-17) (but not truncated Dynorphin-A(2-17) which lacks KOR binding) triggers ERK1/2 phosphorylation, and IFN-γ upregulates KOR expression at both transcriptional and protein levels.\",\n      \"method\": \"FACS, immunocytochemistry, Western blot (ERK1/2 phosphorylation), RT-PCR, IFN-γ stimulation\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional signaling assay with appropriate negative control (Dynorphin-A(2-17)), single lab\",\n      \"pmids\": [\"22424981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"KOR-Cre knockin mice, in which Cre replaces the initial OPRK1 coding sequence, revealed that KOR is expressed in cerebral cortex, nucleus accumbens, striatum, as well as non-neuronal tissues including epithelium, heart, lung, liver, and retinal bipolar/amacrine cells, with recombination detectable by embryonic day 14.5.\",\n      \"method\": \"Knockin mouse (Cre recombinase replacing Oprk1 coding sequence), reporter recombination assay, immunohistochemistry, live imaging\",\n      \"journal\": \"Genesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct genetic reporter of endogenous Oprk1 expression, cell-type localization validated in vivo\",\n      \"pmids\": [\"26575788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Dynorphin peptides promiscuously stimulate G protein signaling (measured by [35S]GTPγS binding) at multiple receptors in striatal membranes and are not selective for KOR; by contrast, the small-molecule agonist U69,593 is highly selective for KOR in this endogenous system. norBNI and 5'GNTI maintain full potency and efficacy against dynorphin-stimulated signaling even in KOR knockout striatum, demonstrating their non-selectivity for KOR in this context.\",\n      \"method\": \"[35S]GTPγS binding assay in striatal membrane preparations from WT, KOR-KO, and MOR-KO mice; pharmacological characterization of agonists and antagonists\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — rigorous in vitro assay in endogenous tissue using multiple genetic controls (KO mice), replicated across ligand classes\",\n      \"pmids\": [\"26160155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"VTA KOR activation mediates aversion-induced reductions in striatal dopamine required for learned avoidance: intra-VTA KOR blockade attenuated real-time aversion-induced dopamine decreases and prevented avoidance behavior; intra-nucleus accumbens D2 receptor agonism (mimicking reduced dopamine tone) also prevented avoidance, placing VTA KOR upstream of dopamine-dependent striatal aversion circuitry.\",\n      \"method\": \"Site-specific pharmacology (intra-VTA norBNI), real-time dopamine voltammetry, intra-NAc D2 agonism, behavioral avoidance assay in rats\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic/pharmacological epistasis with real-time neurochemical readout and behavioral endpoint, mechanistic pathway defined\",\n      \"pmids\": [\"32057802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"The KOR structure in complex with the antagonist JDTic (crystal structure solved in 2012) and a more recent active-state KOR structure together reveal atomic details of the ligand binding pocket, subtype selectivity determinants, and receptor activation mechanisms including distinct contacts for agonists versus antagonists.\",\n      \"method\": \"X-ray crystallography (inactive state with JDTic); structural determination of active state KOR\",\n      \"journal\": \"Handbook of experimental pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystallographic structures of both inactive and active receptor states with functional pharmacological validation\",\n      \"pmids\": [\"33945028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Activation of KOR by famotidine (identified via structure-based virtual screening) promotes oligodendrocyte precursor cell (OPC) maturation and CNS remyelination through the KOR/STAT3 signaling pathway, as demonstrated in vitro and in vivo demyelinating disease models.\",\n      \"method\": \"Structure-based virtual screening, in vitro OPC differentiation assays, in vivo remyelination model, Western blot (STAT3 pathway), pharmacological validation\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — complementary in vitro and in vivo models with pathway identification (KOR/STAT3), single lab\",\n      \"pmids\": [\"38692525\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Overexpression of Oprk1 in VTA dopaminergic neurons (using TH::Cre rats with conditional inducible Cre-Lox system) recapitulated phenotypes of alcohol dependence, including escalated alcohol self-administration and depressive-like behavior, demonstrating that KOR signaling specifically within VTA DA neurons is sufficient to drive maladaptive behavioral regulation associated with alcohol dependence.\",\n      \"method\": \"Conditional Oprk1 overexpression (Cre-Lox in TH::Cre rats), operant alcohol self-administration, affective behavior assays, RT-PCR and functional KOR assays in VTA\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cell-type-specific gain-of-function with defined behavioral phenotype, single lab\",\n      \"pmids\": [\"36764577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Activation of KOR inhibits estrogen receptor (ER)-positive breast cancer cell proliferation and promotes apoptosis; gene ontology and PPI network analysis followed by XBP1 silencing experiments identified KOR-ER-XBP1 as the downstream signaling pathway mediating the anti-tumor effects of KOR agonists in MCF-7 and T47D cells.\",\n      \"method\": \"Cell viability and apoptosis assays in ER+ breast cancer cell lines, siRNA knockdown of XBP1, GO/KEGG pathway analysis, PPI network analysis\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional loss-of-function (XBP1 KD) confirms pathway placement, in vitro only, single lab\",\n      \"pmids\": [\"37708692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"KOR knockout (KOR-KO) mice showed significantly increased mechanical allodynia after intra-articular MIA injection compared to WT mice, and demonstrated increased microglial activation in the lumbar spinal cord, alterations in CRF in the amygdala and hippocampus, and down-regulation of histone 3 acetylation in the amygdala, establishing the dynorphin/KOR system's role in modulating nociceptive, emotional, and cognitive dimensions of joint pain.\",\n      \"method\": \"KOR-KO and PDYN-KO mice, MIA joint pain model, behavioral tests (elevated plus maze, object recognition, anhedonia), immunohistochemistry, Western blot\",\n      \"journal\": \"Neuropharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with multiple behavioral and molecular phenotype readouts, single lab\",\n      \"pmids\": [\"27567942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Antisense oligodeoxynucleotide mapping of the three exons of KOR-1 revealed that analgesia produced by dynorphin B and alpha-neoendorphin differs mechanistically from U50,488H analgesia: probes targeting all three exons blocked U50,488H analgesia, while dynorphin B and alpha-neoendorphin showed distinct antisense probe selectivity profiles, indicating they act via different receptor mechanisms (kappa1b site) despite sharing sensitivity to norBNI.\",\n      \"method\": \"Antisense oligodeoxynucleotide exon mapping in vivo (mouse analgesia), kappa1-selective antagonist (norBNI) challenge\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic antisense mapping across all three exons with multiple ligands, single lab\",\n      \"pmids\": [\"10224306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"miR-144-3p directly suppresses Oprk1/KOR expression: luciferase assay confirmed that miR-144-3p exerts an inhibitory effect on Oprk1 expression in PC12 cells; nicotine dependence and withdrawal decreased miR-144-3p and increased Oprk1/KOR in prefrontal cortex, nucleus accumbens, and hippocampus.\",\n      \"method\": \"miRNA sequencing, qRT-PCR, Western blot, luciferase reporter assay for miR-144-3p/Oprk1 interaction\",\n      \"journal\": \"Nicotine & tobacco research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — luciferase assay validates miR-144-3p targeting of Oprk1 3'UTR, single lab\",\n      \"pmids\": [\"37455648\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Activation of KOR in the insular cortex blocked pain-related aversive memory behaviors, and subsequent experiments showed that activation of GABAergic neurons in the insular cortex reversed the effect of KOR activation, placing KOR upstream of GABAergic neuron activity in this circuit; electroacupuncture-mediated block of pain aversive memory was reversed by either GABAergic neuron activation or KOR inhibition in the insular cortex.\",\n      \"method\": \"Chemogenetics (DREADD), pharmacology (KOR agonist/antagonist injection into insular cortex), behavioral assays (carrageenan pain-aversive memory model) in mice\",\n      \"journal\": \"Cerebral cortex\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — chemogenetic and pharmacological epistasis with defined circuit position, single lab\",\n      \"pmids\": [\"37679857\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Difelikefalin (peripherally restricted KOR agonist) produces diuresis predominantly through central KOR pathways: ICV norBNI (central KOR blockade) markedly attenuated difelikefalin-induced urine output, while peripheral norBNI prevented all responses; electrolyte reabsorption effects were mediated through peripheral KOR pathways, demonstrating distinct central vs. peripheral KOR pathway functions for diuresis and electrolyte handling.\",\n      \"method\": \"ICV vs. IV norBNI pretreatment in conscious catheterized rats, urine output and electrolyte measurements, cardiovascular monitoring\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection of central vs. peripheral KOR pathways with functional readouts, single lab\",\n      \"pmids\": [\"36202183\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"KOR immunoreactivity was found predominantly in OFF (86%) and NEUTRAL (80%) cells but rarely in ON (13%) cells in the rostral ventromedial medulla (RVM); most KOR-immunoreactive cells (16 of 17) also contained GAD67, identifying KOR-expressing neurons in the RVM as predominantly GABAergic, consistent with KOR agonists directly inhibiting off and neutral cell activity.\",\n      \"method\": \"Extracellular recording of RVM neurons in vivo, juxtacellular biotinamide labeling, immunofluorescence for KOR and GAD67\",\n      \"journal\": \"Journal of neurophysiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct co-localization of functional cell-type classification with KOR and GAD67 immunoreactivity, single lab\",\n      \"pmids\": [\"17005613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Dynorphin/KOR system inhibits neuronal autophagy by activating the mTOR signaling pathway: overexpression of prodynorphin in epileptic rats activated mTOR, inhibited autophagy markers (LC3, GFP-LC3 puncta), and reduced neuronal apoptosis; rapamycin (mTOR inhibitor) reversed the dynorphin/KOR-mediated anti-autophagy and anti-apoptotic effects in Mg2+-free-induced seizure-like neurons.\",\n      \"method\": \"Prodynorphin overexpression in vivo (pilocarpine epilepsy model), Mg2+-free in vitro seizure model, Western blot (mTOR pathway), TUNEL/flow cytometry apoptosis, GFP-LC3 autophagy assay, pharmacological rescue with rapamycin\",\n      \"journal\": \"Cell biology international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo models with pharmacological epistasis (rapamycin rescue), single lab\",\n      \"pmids\": [\"35989483\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Triazole 187, a G protein signaling-biased KOR agonist, suppresses itch without sedation (no reduction in spontaneous locomotion) and produces anxiolytic-like behaviors, demonstrating that G protein-biased KOR agonism can dissociate antipruritic effects from sedation; it also produces markedly less diuresis (30% of U50,488H at 188-fold the antipruritic potency dose) compared to unbiased KOR agonists.\",\n      \"method\": \"In vitro G protein/β-arrestin signaling assays, behavioral pharmacology (locomotion, itch, anxiety, diuresis) in mice\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1-2 — biased signaling characterization with multiple behavioral endpoint dissociation, preprint, single lab\",\n      \"pmids\": [\"40027836\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"OPRK1 encodes the kappa opioid receptor (KOR), a GPCR that, upon activation by dynorphin or exogenous agonists, couples to Gαi/o to inhibit cAMP (requiring peripheral AC3 for full signaling), activates ERK1/2 and p38 MAPK, and undergoes GRK-mediated phosphorylation at Ser369 in its C-terminal tail initiating β-arrestin-dependent desensitization; KOR activation in the mesolimbic dopamine system (particularly VTA) suppresses dopamine release to mediate aversive learning and modulate reward, while its expression is regulated epigenetically by promoter methylation and by miR-144-3p, and a functional insertion/deletion in the promoter region reduces transcription by ~50%, contributing to individual differences in addiction vulnerability.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"OPRK1 encodes the kappa opioid receptor (KOR), a Gαi/o-coupled GPCR activated by dynorphin peptides and selective synthetic agonists such as U50,488H that functions as a central modulator of nociception, aversion, reward, and affective behavior. KOR activation inhibits cAMP production — requiring adenylyl cyclase 3 in peripheral sensory neurons — and engages downstream ERK1/2, p38 MAPK, mTOR, and STAT3 signaling pathways; agonist-stimulated GRK phosphorylation at C-terminal residues (including Ser369) initiates β-arrestin-dependent desensitization, with phosphorylation-site mutations revealing sex-dependent roles in tolerance and conditioned place aversion [PMID:34736959, PMID:21370032, PMID:34914639, PMID:22424981]. Within the mesolimbic dopamine system, VTA KOR activation suppresses striatal dopamine release to drive aversive learning and avoidance behavior, and cell-type-specific KOR overexpression in VTA dopaminergic neurons is sufficient to escalate alcohol self-administration and produce depressive-like phenotypes [PMID:32057802, PMID:36764577]. OPRK1 transcription is repressed by a functional promoter insertion/deletion variant and by CpG methylation, and post-transcriptionally suppressed by miR-144-3p targeting the 3′UTR [PMID:18319328, PMID:26300544, PMID:37455648].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Antisense exon mapping revealed that endogenous dynorphin peptides and synthetic KOR agonists engage distinct receptor mechanisms despite shared antagonist sensitivity, establishing that OPRK1 gene products can mediate pharmacologically distinguishable kappa opioid activities.\",\n      \"evidence\": \"Antisense oligodeoxynucleotide targeting of KOR-1 exons in mouse analgesia models with multiple ligands\",\n      \"pmids\": [\"10224306\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular identity of the kappa1b site was not resolved\", \"No receptor mutagenesis or binding data to confirm distinct receptor configurations\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identification of KOR expression predominantly on GABAergic OFF and NEUTRAL cells in the rostral ventromedial medulla established a circuit-level mechanism for KOR modulation of descending pain control.\",\n      \"evidence\": \"Juxtacellular labeling with immunofluorescence for KOR and GAD67 in functionally classified RVM neurons in vivo\",\n      \"pmids\": [\"17005613\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of KOR activation on these specific cell types was not directly tested electrophysiologically\", \"Whether RVM KOR modulates affective versus sensory pain dimensions was not addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"A functional insertion/deletion variant upstream of the OPRK1 coding region was shown to halve transcriptional activity, providing the first direct evidence that cis-regulatory variation modulates KOR expression levels.\",\n      \"evidence\": \"Luciferase reporter promoter assays with allele-specific constructs\",\n      \"pmids\": [\"18319328\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Effect on endogenous KOR protein levels in human tissue not demonstrated\", \"Association with addiction phenotypes was suggestive but not definitive\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Development and validation of phospho-Ser369-specific antibodies confirmed that GRK-mediated phosphorylation of KOR's C-terminal tail is an in vivo marker of receptor activation, linking agonist exposure and stress to a defined post-translational modification.\",\n      \"evidence\": \"Phospho-selective antibody immunohistochemistry following behavioral and pharmacological manipulation in rodents\",\n      \"pmids\": [\"21370032\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Contribution of specific GRK isoforms was not determined\", \"Downstream consequences of Ser369 phosphorylation beyond β-arrestin recruitment were not dissected\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Demonstration that KOR on macrophages signals through ERK1/2 upon dynorphin-A stimulation, with IFN-γ upregulating KOR expression, extended KOR function beyond neurons to immune cells.\",\n      \"evidence\": \"Western blot for phospho-ERK1/2 in J774 macrophages stimulated with Dynorphin-A(1-17) vs. truncated control\",\n      \"pmids\": [\"22424981\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance of macrophage KOR signaling in vivo not established\", \"Whether ERK activation leads to cytokine modulation was not tested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Three advances refined KOR biology: crystal structures of inactive (JDTic-bound) KOR revealed subtype selectivity determinants; CpG methylation of the OPRK1 promoter was shown to suppress transcription; and KOR-Cre knockin mice mapped KOR expression across brain regions and peripheral tissues from embryonic day 14.5.\",\n      \"evidence\": \"X-ray crystallography; luciferase reporter assay with bisulphite pyrosequencing; Cre-reporter recombination mapping in knockin mice\",\n      \"pmids\": [\"33945028\", \"26300544\", \"26575788\", \"26160155\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Active-state KOR structure dynamics and G protein coupling interface not fully resolved at this time\", \"Functional consequences of KOR expression in non-neuronal tissues remain largely unexplored\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Intra-VTA KOR blockade attenuated real-time dopamine decreases and avoidance behavior, placing VTA KOR upstream of striatal dopamine signaling in aversion-driven learned avoidance and defining a circuit mechanism for KOR-mediated dysphoria.\",\n      \"evidence\": \"Site-specific norBNI infusion with fast-scan cyclic voltammetry for dopamine and behavioral avoidance assay in rats\",\n      \"pmids\": [\"32057802\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-type specificity of VTA KOR (dopaminergic vs. GABAergic neurons) was not resolved\", \"Whether this circuit mediates stress-induced relapse to drug seeking was not directly tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Knockin mice lacking four C-terminal KOR phosphorylation sites revealed that receptor phosphorylation mediates tolerance and conditioned place aversion in a sex-dependent manner, dissociating phosphorylation-dependent from phosphorylation-independent behavioral outputs.\",\n      \"evidence\": \"K4A knockin mice with behavioral pharmacology (anti-scratch tolerance, conditioned place aversion, locomotion)\",\n      \"pmids\": [\"34736959\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for the sex difference (hormonal vs. circuit) was not identified\", \"Which of the four residues is most critical was not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Multiple studies in 2022 expanded the KOR signaling repertoire: AC3 was identified as essential for peripheral KOR/Gαi-o coupling to Kv channels and analgesia; dynorphin/KOR was shown to inhibit autophagy via mTOR; KOR overexpression in VTA DA neurons recapitulated alcohol dependence phenotypes; and central vs. peripheral KOR pathways were pharmacologically dissected for diuresis vs. electrolyte handling.\",\n      \"evidence\": \"AC3 conditional KO with electrophysiology; prodynorphin overexpression with rapamycin rescue in epilepsy models; Cre-Lox Oprk1 overexpression in TH::Cre rats; ICV vs. IV norBNI with renal function readouts\",\n      \"pmids\": [\"34914639\", \"35989483\", \"36764577\", \"36202183\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AC3-KOR interaction is direct or scaffolded remains unclear\", \"mTOR pathway activation by KOR needs confirmation beyond epilepsy context\", \"How VTA KOR overexpression interacts with endogenous dynorphin tone is unknown\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Post-transcriptional regulation of OPRK1 by miR-144-3p was validated, and KOR's circuit-level role in pain-aversive memory was placed upstream of insular cortex GABAergic neurons, while KOR/STAT3 signaling was linked to oligodendrocyte precursor cell maturation and remyelination.\",\n      \"evidence\": \"Luciferase 3′UTR reporter assay for miR-144-3p; DREADD chemogenetics with intra-insular KOR pharmacology; virtual screening with in vitro OPC differentiation and in vivo demyelination models\",\n      \"pmids\": [\"37455648\", \"37679857\", \"38692525\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"miR-144-3p regulation of OPRK1 not confirmed in human tissue\", \"KOR/STAT3 pathway in remyelination demonstrated with repurposed drug (famotidine) whose selectivity for KOR over H2R in vivo needs clarification\", \"Insular cortex findings are from a single pain model\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of biased agonism at KOR (G protein vs. β-arrestin pathways), the molecular determinants of sex-dependent KOR phosphorylation effects, the physiological roles of KOR in non-neuronal tissues identified by expression mapping, and whether KOR-targeted therapies can achieve pathway-selective efficacy in humans.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No human clinical validation of biased KOR agonism for dissociating therapeutic from adverse effects\", \"Structural basis for agonist-induced conformational bias at KOR not resolved at atomic level\", \"KOR function in peripheral immune and epithelial cells remains largely unexplored mechanistically\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [5, 7, 8, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [5, 6, 9]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 4, 5, 8, 10, 19]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [8, 11, 16, 18]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"ADCY3\",\n      \"GRK3\",\n      \"ARRB2\",\n      \"PDYN\",\n      \"STAT3\",\n      \"MTOR\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}